Balboa Capital Corporation – Trademark Portfolio
Entity Type: 03
Balboa Capital Corporation holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 11 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include PORTAL360, BALBOA CAPITAL, and BALBOA CAPITAL A DIVISION OF AMERIS BANK. The owner is based in Irvine, CA.
2010 Main Street, Suite 1150
Irvine, CA 92614
Showing of trademarks Trademarks
Trademark Classifications
Balboa Capital Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Balboa Capital Corporation have?
Balboa Capital Corporation has 11 U.S. trademarks filed with the USPTO. Of these, 5 registered, 4 abandoned, 2 cancelled.
What trademark classes does Balboa Capital Corporation file in?
Balboa Capital Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 42 (Computer & Scientific). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are Balboa Capital Corporation's most well-known trademarks?
Balboa Capital Corporation's registered trademark portfolio includes well-known marks such as PORTAL360, BALBOA CAPITAL, and BALBOA CAPITAL A DIVISION OF AMERIS BANK. These are among 5 currently registered trademarks in the portfolio.
What is Balboa Capital Corporation's trademark registration success rate?
Balboa Capital Corporation has a 45% trademark registration rate, with 5 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.